TRINETRA › Sectors › Healthcare
Solara Active Pharma Sciences Limited (SOLARA) — share price, P/E and fundamentals
Solara Active Pharma Sciences Limited (NSE: SOLARA) closed at ₹632.60 on 30 Oct 2026, +5.8% over one year, against a 52-week range of ₹422.00 – ₹774.00.
In the quarter ended 30 Sept 2026 (consolidated, filed 16 Oct 2026) it reported revenue of ₹417 cr and net profit of ₹28 cr, a 6.8% net margin; revenue grew 33.1% year on year.
On four consecutive filed quarters its trailing P/E is 82.5; since 15 May 2025 its own P/E has ranged from 78.4 to 4,978.6 (median 4,185.7), and today's reading is higher than 1% of those 191 trading days.
From the balance sheet dated 30 Sept 2026: return on equity 7.9%, ROCE 11.0%, debt-to-equity 0.40, Piotroski F-score 7 of 9.
Against 66 Healthcare peers on NSE: Net margin higher than 16% of 64 sector peers; PBT margin higher than 14% of 64 sector peers; ROE higher than 16% of 64 sector peers.
Key figures
| Last close | ₹632.60 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -13.0% / +32.5% / +5.8% |
| 52-week low – high | ₹422.00 – ₹774.00 |
| Market capitalisation | ₹3,047 cr |
| Trailing P/E | 82.5 |
| Price / book | 2.12 |
| EV / EBITDA | 15.5 |
| Earnings yield | 1.2% |
| TTM EPS | ₹7.67 |
| TTM net profit | ₹37 cr |
| Quarter revenue | ₹417 cr |
| Quarter net profit | ₹28 cr |
| Net margin | 6.8% |
| Revenue growth (YoY) | +33.1% |
| Return on equity | 7.9% |
| ROCE | 11.0% |
| Debt / equity | 0.40 |
| Current ratio | 1.32 |
| Free cash flow | ₹9 cr |
| Piotroski F-score | 7 / 9 |
| Average daily turnover (50 days) | ₹19.9 cr |
Against Healthcare peers
| Metric | SOLARA | Peer median | Percentile |
|---|---|---|---|
| Net margin | 6.82 | 12.89 | 16 |
| PBT margin | 6.82 | 17.68 | 14 |
| ROE | 7.93 | 13.87 | 16 |
| ROCE | 10.96 | 17.26 | 19 |
| Debt / equity | 0.40 | 0.11 | 79 |
| FCF margin | 1.07 | -0.87 | 53 |
| Cash conversion | 1.42 | 1.25 | 63 |
| Trailing P/E | 82.47 | 43.26 | 83 |
Questions
What is the P/E ratio of Solara Active Pharma Sciences Limited?
Solara Active Pharma Sciences Limited's trailing P/E is 82.5, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Sept 2026. Since 15 May 2025 its P/E has ranged 78.4–4,978.6.
What were Solara Active Pharma Sciences Limited's latest quarterly results?
For the quarter ended 30 Sept 2026, Solara Active Pharma Sciences Limited reported revenue of ₹417 cr and net profit of ₹28 cr (consolidated), filed with the exchange on 16 Oct 2026.
What is Solara Active Pharma Sciences Limited's ROE?
Return on equity is 7.9% based on the balance sheet dated 30 Sept 2026.
Does Solara Active Pharma Sciences Limited have debt?
Debt-to-equity is 0.40 on the balance sheet dated 30 Sept 2026.
What is SOLARA's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, SOLARA traded between ₹422.00 and ₹774.00.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Sept 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.